期刊文献+

原发性血小板增多症患者Jak2-v617f突变与急性冠脉综合征的相关性 被引量:1

下载PDF
导出
摘要 目的:通过比较原发性血小板增多症(ET)患者中Jak2-v617f突变阳性患者与阴性患者急性冠脉综合征发病率的差异,探讨Jak2-v617f突变与急性冠脉综合征(ACS)的相关性。方法:选择2004-2015年于唐山开滦总医院及唐山市人民医院住院并确诊为ET的68例患者,应用等位基因特异性聚合酶链反应(AS-PCR)检测Jak2-v617f点突变,比较Jak2-v617f点突变阳性与阴性两组患者的ACS发病率。结果:68例ET患者中有28例存在Jak2-v617f点突变,突变率为41%。Jak2-v617f点突变阳性和阴性两组患者ACS发生率分别为21.0%和5.0%,差异有统计学意义(P<0.05)。结论:AS-PCR检测原发性血小板增多症患者中Jak2-v617f点突变阳性率为41%,Jak2-v617f点突变阳性的原发性血小板增多症患者易患急性冠脉综合征。
出处 《中外医学研究》 2016年第12期149-150,共2页 CHINESE AND FOREIGN MEDICAL RESEARCH
  • 相关文献

参考文献6

  • 1Harrison C N, Campbell P J, Buck G, et al.Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia[J].N Engl J Med, 2005, 353(1): 33-45.
  • 2De S V, Za T, Rossi E, et al.Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia[J].Haematologica, 2009, 94(94): 733-737.
  • 3Campbell P J, MacLean C, Beer P A, et al.Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospectivePT1 cohort[J].Blood, 2012, 120(7): 1409-1411.
  • 4邹丽芳,姚一芸,朱琦,窦红菊,陈琼,胡钧培.骨髓增殖性肿瘤患者止凝血功能的改变[J].血栓与止血学,2014,20(4):164-167. 被引量:7
  • 5Landolfi R, Di Gennaro L, Falanga A.Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation[J].Leukemia, 2008, 22(11) : 2020-2028.
  • 6张晟瑜,杨明,曾勇,韩业晨,王书杰,沈珠军,张抒扬,方全.骨髓增殖性肿瘤患者并发急性冠脉综合征相关因素分析[J].基础医学与临床,2015,35(4):514-517. 被引量:3

二级参考文献24

  • 1TEFFERI A,THIELE J, VARDIMAN J W. The 2008 World Health Organization classification system for myeloprolifera- rive neoplasma[ J ]. Cancer ,2009,115 ( 17 ) :3842-3847.
  • 2TEFFERIA A,THIELE J, ORAZI A, et al. Proposals and ra- tionale for revision of the World. Health Organization diag- nostic. Criteria for polycythemia vera, essential thrombocy- themia, and primary myelofibrosis: Recommendations from an ad hoc internation expert panel [ J ]. Blood, 2007,110 : 1092-1097.
  • 3BAXTER, EJ, SCOTF LM, CAMPBEL DJ, et al. Acguired mutation of the tyrosinek kinase JAK2 in human myeloprolif- erative disorders [ J ]. Lancet,2005,365 : 1054-1061.
  • 4TEFFERI A, VARDIMAN JW. Classification and diagnosis of myeloprolifentive neoplasma:The 2008 world Health Or-ganization criteria and point of care diagnostic algorithms [ J]. Leukemia ,2008,22 : 14-22.
  • 5VANNUECHI AM, ANATONIOLI E, GUGLIELMELLI P, et al. Chinical profile of homozygous JAK2V617F mutation in patients with polycythemia vera of essential thrombotythemia [J ]. Blood,2005,110 ( 3 ): 840- 846.
  • 6PAPADAKIS E, HOFFMAN R, BRENNTER B. Thrombohe- morrhagic complications of myeloproliferative disarders [ J ]. Blood Rev ,2010,24:227-232.
  • 7SUN T, ZHANG L. Thrombosis in myeloproliferative neo- plasma with JAK2V617F mutation [ J]. Clin Appl Thromb Hemost,2012,23. [Epub ahead of printl.
  • 8VANNUVCHI AM, ANTONIOLI E, GUGLIELMELLI P, et al. Chinical profile of homezygous JAK2V617F mutation in patients with polycythemia vera or essential thrombocythemia [ J ]. Blood,2007,110 ( 3 ) .. 800- 846.
  • 9Campbell PJ,Green AR. The myeloproliferative disorders[J]. N Engl J Med, 2006, 355: 2452-2466.
  • 10Papadakis E, Hoffman R, Brenner B. Thrombohemorrhagiccomplications of myeloproliferative disorders [ J ]. BloodRev, 2010, 24:227-232.

共引文献8

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部